← Leaderboards
Gabor J Tigyi
University Of Tennessee Health Sci Ctr
$24,190,037
Attributed
$27,065,116
Total exposure
20
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,065,116 · 19
VA$0 · 1
By mechanism
R01$14,522,692 · 5
C06$3,115,346 · 1
U01$2,871,090 · 1
RC2$2,321,862 · 1
U19$1,534,721 · 2
RC1$1,449,896 · 1
Top collaborators
- Corinne Elizabeth Augelli-Szafran4 shared
- Sue Chin Lee4 shared
- Raul Martin Torres4 shared
- Jur Strobos2 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Mostafa Waleed Gaber$272,225
- Jur Strobos$539,515
- Duane D Miller$5,855,110
- Anjaparavanda P Naren$16,948,975
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogPharmaceutical PreparationsLysophosphatidic AcidBaseReceptorPropertyFundingGrowth FactorRadiationLigandsIn VivoG-Protein-Coupled ReceptorsIrradiationMolecularIn VitroRadiation InjuriesDrug KineticsDoseLysophosphatidic Acid ReceptorsLeadSmall MoleculeGastrointestinalScaffoldLysophospholipids
Grant awards (73)
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$729,283
R01 · FY2025 · CA · contact PI
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$712,726
R01 · FY2024 · CA · contact PI
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator$286,130
U19 · FY2024 · AI · contact PI
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$810,231
R01 · FY2023 · CA · contact PI
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator$310,386
U19 · FY2023 · AI · contact PI
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator$23,254
U19 · FY2023 · AI · contact PI
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR$861,845
R01 · FY2022 · CA · contact PI
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator$296,245
U19 · FY2022 · AI · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$292,473
R01 · FY2022 · CA · contact PI
Radiobiology Research Suite Expansion of the TriMetis GLP Vivarium at UTHSC$3,115,346
C06 · FY2021 · OD · contact PI
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator$301,081
U19 · FY2021 · AI · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$298,443
R01 · FY2021 · CA · contact PI
IND-enabling development of Radioprotectin 1: a dual GI/HE radiation mitigator$317,625
U19 · FY2020 · AI · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$298,443
R01 · FY2020 · CA · contact PI
Targeted Therapies for the Treatment of GI-ARS Diarrhea$252,128
R41 · FY2020 · DK · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$289,488
R01 · FY2019 · CA · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$298,443
R01 · FY2018 · CA · contact PI
IND-Enabling Preclinical Development of a New Radiomitigator$210,468
U01 · FY2018 · AI · contact PI
IND-Enabling Preclinical Development of a New Radiomitigator$436,361
U01 · FY2017 · AI · contact PI
IND-Enabling Preclinical Development of a New Radiomitigator$662,618
U01 · FY2016 · AI · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$297,491
R01 · FY2016 · CA · contact PI
Novel Radiomitigators Targeting LPA Receptors$0
I01 · FY2016 · VA · contact PI
IND-Enabling Preclinical Development of a New Radiomitigator$482,613
U01 · FY2015 · AI · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$297,491
R01 · FY2015 · CA · contact PI
Novel Radiomitigators Targeting LPA Receptors$0
I01 · FY2015 · VA · contact PI
IND-Enabling Preclinical Development of a New Radiomitigator$563,189
U01 · FY2014 · AI · contact PI
GI Hormones and Other Factors in Growth of Mucosa$509,243
R37 · FY2014 · DK · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$289,149
R01 · FY2014 · CA · contact PI
Novel Radiomitigators Targeting LPA Receptors$0
I01 · FY2014 · VA · contact PI
IND-Enabling Preclinical Development of a New Radiomitigator$515,841
U01 · FY2013 · AI · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$284,228
R01 · FY2013 · CA · contact PI
Novel Radiomitigators Targeting LPA Receptors$0
I01 · FY2013 · VA · contact PI
Analysis of Radiomitigative Cell Signaling$465,362
R01 · FY2012 · AI · contact PI
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis$302,203
R01 · FY2012 · CA · contact PI
Analysis of Radiomitigative Cell Signaling$9,326
R01 · FY2012 · AI · contact PI
Analysis of Radiomitigative Cell Signaling$463,885
R01 · FY2011 · AI · contact PI
DEVELOPMENT OF A NOVEL GASTROINTESTINAL RADIOMITIGATOR$75,629
P51 · FY2011 · RR · contact PI
PRECLINICAL DEVELOPMENT OF A GI RADIATION COUNTERMEASURE$75,629
P51 · FY2011 · RR · contact PI
Preclinical Development of a GI Radiation Countermeasure$1,076,912
RC2 · FY2010 · AI · contact PI
Analysis of Radiomitigative Cell Signaling$369,762
R01 · FY2010 · AI · contact PI
Ligand Recognition by Phospholipid Growth Factor Receptors$285,473
R01 · FY2010 · CA · contact PI
PRECLINICAL DEVELOPMENT OF A GI RADIATION COUNTERMEASURE$114,105
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF A NOVEL GASTROINTESTINAL RADIOMITIGATOR$114,105
P51 · FY2010 · RR · contact PI
Preclinical Development of a GI Radiation Countermeasure$1,244,950
RC2 · FY2009 · AI · contact PI
Development of a Novel Gastrointestinal Radiomitigator$449,896
RC1 · FY2009 · AI · contact PI
Analysis of Radiomitigative Cell Signaling$374,037
R01 · FY2009 · AI · contact PI
Ligand Recognition by Phospholipid Growth Factor Receptors$285,624
R01 · FY2009 · CA · contact PI
DEVELOPMENT OF A NOVEL GASTROINTESTINAL RADIOMITIGATOR$106,670
P51 · FY2009 · RR · contact PI
Analysis of Radiomitigative Cell Signaling$371,393
R01 · FY2008 · AI · contact PI
Analysis of LPA Signaling through the GPCR-PPARgamma Axis$346,086
R01 · FY2008 · HL · contact PI
Ligand Recognition by Phospholipid Growth Factor Receptors$285,763
R01 · FY2008 · CA · contact PI
Development of a Novel Gastrointestinal Radiomitigator$1,000,000
RC1 · FY2007 · AI · contact PI
Analysis of LPA Signaling through the GPCR-PPARgamma Axis$346,086
R01 · FY2007 · HL · contact PI
Ligand Recognition by Phospholipid Growth Factor Receptors$285,892
R01 · FY2007 · CA · contact PI
Analysis of LPA Signaling through the GPCR-PPARgamma Axis$356,423
R01 · FY2006 · HL · contact PI
Ligand Recognition by Phospholipid Growth Factor Receptors$317,552
R01 · FY2006 · CA · contact PI
Therapeutically Promising Phospholipid Growth Factors$314,191
R01 · FY2006 · HL · contact PI
Analysis of LPA Signaling through the GPCR-PPAR Axis$359,940
R01 · FY2005 · HL
Therapeutically Promising Phospholipid Growth Factors$321,750
R01 · FY2005 · HL
Ligand recognition by growth factor receptors$275,632
R01 · FY2005 · CA
Ligand recognition by growth factor receptors$65,970
R01 · FY2005 · CA
Therapeutically Promising Phospholipid Growth Factors$321,750
R01 · FY2004 · HL
Ligand recognition by growth factor receptors$276,328
R01 · FY2004 · CA
Ligand recognition by growth factor receptors$46,329
R01 · FY2004 · CA
Ligand recognition by growth factor receptors$27,579
R01 · FY2004 · CA
Therapeutically Promising Phospholipid Growth Factors$321,750
R01 · FY2003 · HL
Ligand recognition by growth factor receptors$276,998
R01 · FY2003 · CA
2003 FASEB Summer Conference on Lysophospholipids$2,000
R13 · FY2003 · AI
Ligand recognition by growth factor receptors$277,642
R01 · FY2002 · CA
THERAPEUTICALLY PROMISING PHOSPHOLIPID GROWTH FACTORS$247,917
R01 · FY2002 · HL
Ligand recognition by growth factor receptors$284,199
R01 · FY2001 · CA
THERAPEUTICALLY PROMISING PHOSPHOLIPID GROWTH FACTORS$242,300
R01 · FY2001 · HL
THERAPEUTICALLY PROMISING PHOSPHOLIPID GROWTH FACTORS$237,816
R01 · FY2000 · HL